12th International Congress on Myeloproliferative Neoplasms

 

12th International Congress on Myeloproliferative Neoplasms
Avatar

Tales from the Clinic on Essential Thrombocytosis: No Therapy for Asymptomatic Disease, Chemo is Toxic/Ineffective for Platelet Count Reduction, Ruxolitinib to Be Established

By 12th International Congress on Myeloproliferative Neoplasms FEATURING Jerry L. Spivak
By 12th International Congress on Myeloproliferative Neoplasms FEATURING Jerry L. Spivak
0 views
November 25, 2019
Comments 0
Login to view comments. Click here to Login

Featured Video

08:18
Insights from 2023 ASH Annual Meeting

Treatment Strategies for Hematocrit Control in PV

Feat. A. Zhou

Featured Video

16:26
Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison
Latest Advances in Myeloproliferative Neoplasms
19:58
12th International Congress on Myeloproliferative Neoplasms

How Should We Treat Children w/ MPN: No Guidelines on Cytoreduction …

Feat. N. Kucine
22:49
12th International Congress on Myeloproliferative Neoplasms

Old and New Myelofibrosis (MF) Classifications, When to Consider Tra…

Feat. H. Deeg
28:48
12th International Congress on Myeloproliferative Neoplasms

Introduction to Hypoxia and Erythropoiesis in the Context of High Al…

Feat. J. Prchal
26:03
12th International Congress on Myeloproliferative Neoplasms

Moving Beyond JAKi: Ruxolitinib Failure, Newly Approved and in Devel…

Feat. N. Pemmaraju
28:30
12th International Congress on Myeloproliferative Neoplasms

Is There a Role of Transplantation for CML in the Era of TKIs?

Feat. K. Van Besien
16:32
12th International Congress on Myeloproliferative Neoplasms

What Are the Risk Factors for Accelerated/Blast Phase MPN and the Ou…

Feat. O. Odenike
08:25
12th International Congress on Myeloproliferative Neoplasms

What is the Molecular Landscape of Blast Phase MPN and the Implicati…

Feat. O. Odenike
06:52
12th International Congress on Myeloproliferative Neoplasms

Targeting Dysregulated Iron Metabolism in Polycythemia Vera (PV) Pat…

Feat. R. Hoffman
08:25
12th International Congress on Myeloproliferative Neoplasms

Therapeutic Options for Treating MPNs are Finally Expanding: Targeti…

Feat. R. Hoffman
11:27
12th International Congress on Myeloproliferative Neoplasms

Therapeutic Options for MPNs are Finally Expanding: Immunotherapies …

Feat. R. Hoffman
17:00
12th International Congress on Myeloproliferative Neoplasms

Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-F…

Feat. R. Silver
07:54
12th International Congress on Myeloproliferative Neoplasms

Update on Long Acting Interferons in MPN: Who Should Be Treated, Who…

Feat. H. Gisslinger
25:17
12th International Congress on Myeloproliferative Neoplasms

Wrangling the MPN-Related Symptom Burden: Specific Symptoms and Etio…

Feat. R. Scherber
26:23
12th International Congress on Myeloproliferative Neoplasms

Update on Myeloid Variant Hypereosinophilia Syndrome: Clinical Subty…

Feat. A. Klion
30:14
12th International Congress on Myeloproliferative Neoplasms

Tales from the Clinic on Essential Thrombocytosis: No Therapy for As…

Feat. J. Spivak
13:55
12th International Congress on Myeloproliferative Neoplasms

Review of JAK2V617F and the Concept of the VAF

Feat. A. Moliterno
20:40
12th International Congress on Myeloproliferative Neoplasms

Review of JAK2V617F VAF Associations in the Context of MPN and CHIP:…

Feat. A. Moliterno